Quantcast
Last updated on April 17, 2014 at 14:57 EDT

Medicago to Host Investor Day Event and Webcast

May 14, 2012

QUEBEC CITY, May 14, 2012 /PRNewswire/ – Medicago Inc. (TSX: MDG), a
biopharmaceutical company focused on developing highly effective and
competitive vaccines based on proprietary manufacturing technologies
and Virus-Like Particles (VLPs), today announced that the Company will
host an Investor Day event on May 30, 2012, at the Indigo Hotel, 151
Tatum Drive, Durham, North Carolina The meeting, which also will be
webcast live, will begin promptly at 12:30 p.m. Eastern Time and end at
approximately 1:30 p.m. Eastern Time.

The Investor Day event will feature presentations from Medicago
executives including: Andy Sheldon, Chief Executive Officer; Pierre
Labbe, Chief Financial Officer; and Mike Wanner, Executive Vice
President of Operations. The presentation will include discussions on
the Company’s results, business strategy and outlook into 2013.

Institutional investors and analysts interested in attending the
Investor Day event should contact Catherine Love, Medicago Investor
Relations, to register via telephone at (418) 658-9393 ext. 156 or
email at lovec@medicago.com. Those attending in person will be invited for a tour of the Medicago
commercial production facility in Research Triangle Park, Durham, NC.

Interested parties may listen to the live, audio webcast of the event by
visiting the Company’s website at http://www.medicago.com/Investors/Events-Presentations. To listen by phone, please dial (647) 427-7450 or 1-
888-231-8191(toll-free North America).

Following the call, an audio archive of the webcast will be available on
the Medicago website. A replay will also be available by phone until
June 30, 2012, by dialing 1-855-859-2056, code 77779960.

About Medicago

Medicago is a clinical-stage biopharmaceutical company developing novel
vaccines and therapeutic proteins to address a broad range of
infectious diseases worldwide. The Company is committed to providing
highly effective and competitive vaccines and therapeutic proteins
based on its proprietary VLP and manufacturing technologies. Medicago
is a worldwide leader in the development of VLP vaccines using a
transient expression system which produces recombinant vaccine antigens
in plants. This technology has potential to offer more potent vaccines
with speed and cost advantages over competitive technologies, enabling
the development of a vaccine for testing in approximately one month
after the identification and reception of genetic sequences from a
pandemic strain. This production time frame has the potential to allow
vaccination of the population before the first wave of a pandemic, and
supply large volumes of vaccine antigens to the world market. Medicago
also intends to expand development into other areas such as biosimilars
and biodefense products where the benefits of our technologies can make
a significant difference. Additional information about Medicago is
available at www.medicago.com.

Forward Looking Statements

This news release includes certain forward-looking statements that are
based upon current expectations, which involve risks and uncertainties
associated with Medicago’s business and the environment in which the
business operates. Any statements contained herein that are not
statements of historical facts may be deemed to be forward-looking,
including those identified by the expressions “anticipate”, “believe”,
“plan”, “estimate”, “expect”, “intend”, and similar expressions to the
extent they relate to Medicago or its management. The forward-looking
statements are not historical facts, but reflect Medicago’s current
expectations regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results or events to differ materially from current
expectations, including the matters discussed under “Risk Factors and
Uncertainties” in Medicago’s Annual Information Form filed on March 29,
2012, with the regulatory authorities. Medicago assumes no obligation
to update the forward-looking statements, or to update the reasons why
actual results could differ from those reflected in the forward-looking
statements.

SOURCE Medicago Inc.


Source: PR Newswire